Biofrontera Q3 revenue doubles to $8.9M; net loss widens to $6.3M

Biofrontera Inc.

2023-Q3 EPS reported -$17.57 revenue$23,475,000

Total revenues $8.9M, up 106% YoY, driven by Ameluz adoption and price increase.
Net loss of $6.3M ($4.64 per share) vs net loss of $2.6M ($2.26 per share) in Q3 2022.
Cash and cash equivalents $3.4M; investment in Biofrontera AG shares valued at $3.3M.
Raised $4.5M in registered direct offering at-the-market on November 2, 2023.
Affirms FY2023 revenue growth at least 25% vs 2022; expects cash flow positive within ~1.5 years.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Biofrontera Inc. reported three and nine months ended September 30, 2023 results: revenue $8.9 million, net income $(4.64) per share, EPS $(4.64) per share. Guidance reaffirmed.

Period: three and nine months ended September 30, 2023
Revenue: $8.9 million
Net income: $(4.64) per share
EPS: $(4.64) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenues for the third quarter of 2023 were $8.9 million

View on SEC.gov

Browse all earnings releases →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-040113

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.